{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:04:09Z","timestamp":1795028649029,"version":"4.10.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["N01MH90003"],"award-info":[{"award-number":["N01MH90003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41386-018-0180-z","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T23:13:47Z","timestamp":1534288427000},"page":"2197-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial"],"prefix":"10.1038","volume":"43","author":[{"given":"Manish K.","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Malchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-7590","authenticated-orcid":false,"given":"Bruce D.","family":"Grannemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-1110","authenticated-orcid":false,"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"key":"180_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/da.22217","volume":"31","author":"R Uher","year":"2014","unstructured":"Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31:459\u201371.","journal-title":"Depress Anxiety"},{"key":"180_CR2","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Publishing; Washington, D.C. 2013."},{"key":"180_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/acps.12140","volume":"129","author":"A Koukopoulos","year":"2014","unstructured":"Koukopoulos A, Sani G. DSM-5 criteria for depression with mixed features: a farewell to mixed depression. Acta Psychiatr Scand. 2014;129:4\u201316.","journal-title":"Acta Psychiatr Scand"},{"key":"180_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1176\/appi.ajp.2010.09071011","volume":"167","author":"J Angst","year":"2010","unstructured":"Angst J, Cui L, Swendsen J, Rothen S, Cravchik A, Kessler RC, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010;167:1194\u2013201.","journal-title":"Am J Psychiatry"},{"key":"180_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jad.2014.09.026","volume":"172","author":"RS McIntyre","year":"2015","unstructured":"McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, et al. The prevalence and illness characteristics of DSM-5-defined \u201cmixed feature specifier\u201d in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2015;172:259\u201364.","journal-title":"J Affect Disord"},{"key":"180_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1034\/j.1600-0447.2003.00051.x","volume":"107","author":"T Sato","year":"2003","unstructured":"Sato T, Bottlender R, Schroter A, Moller HJ. Frequency of manic symptoms during a depressive episode and unipolar \u2018depressive mixed state\u2019 as bipolar spectrum. Acta Psychiatr Scand. 2003;107:268\u201374.","journal-title":"Acta Psychiatr Scand"},{"key":"180_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jad.2004.12.004","volume":"85","author":"HS Akiskal","year":"2005","unstructured":"Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated \u201cunipolar\u201d depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005;85:245\u201358.","journal-title":"J Affect Disord"},{"key":"180_CR8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jad.2016.12.033","volume":"210","author":"RS McIntyre","year":"2017","unstructured":"McIntyre RS, Ng-Mak D, Chuang CC, Halpern R, Patel PA, Rajagopalan K, et al. Major depressive disorder with subthreshold hypomanic (mixed) features: a real-world assessment of treatment patterns and economic burden. J Affect Disord. 2017;210:332\u20137.","journal-title":"J Affect Disord"},{"key":"180_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.4088\/JCP.v67n0504","volume":"67","author":"M Maj","year":"2006","unstructured":"Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated \u201cunipolar\u201d major depression: prevalence, phenomenology, and outcome. J Clin Psychiatry. 2006;67:712\u20139.","journal-title":"J Clin Psychiatry"},{"key":"180_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1600-0447.2008.01324.x","volume":"119","author":"DJ Smith","year":"2009","unstructured":"Smith DJ, Forty L, Russell E, Caesar S, Walters J, Cooper C, et al. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr Scand. 2009;119:325\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"180_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1176\/appi.ajp.2015.15060770","volume":"173","author":"T Suppes","year":"2016","unstructured":"Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173:400\u20137.","journal-title":"Am J Psychiatry"},{"key":"180_CR12","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22\u201333.","journal-title":"J Clin Psychiatry"},{"key":"180_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"180_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","volume":"168","author":"AJ Rush","year":"2011","unstructured":"Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168:689\u2013701.","journal-title":"Am J Psychiatry"},{"key":"180_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"180_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573\u201383.","journal-title":"Biol Psychiatry"},{"key":"180_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","volume":"12","author":"SR Wisniewski","year":"2006","unstructured":"Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71\u20139.","journal-title":"J Psychiatr Pract"},{"key":"180_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0006-3223(01)01065-4","volume":"50","author":"E Altman","year":"2001","unstructured":"Altman E, Hedeker D, Peterson JL, Davis JM. A comparative evaluation of three self-rating scales for acute mania. Biol Psychiatry. 2001;50:468\u201371.","journal-title":"Biol Psychiatry"},{"key":"180_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","volume":"42","author":"EG Altman","year":"1997","unstructured":"Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Biol Psychiatry. 1997;42:948\u201355.","journal-title":"Biol Psychiatry"},{"key":"180_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1017\/S0033291700035558","volume":"26","author":"AJ Rush","year":"1996","unstructured":"Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477\u201386.","journal-title":"Psychol Med"},{"key":"180_CR21","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","volume":"59","author":"HC Kraemer","year":"2006","unstructured":"Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59:990\u20136.","journal-title":"Biol Psychiatry"},{"key":"180_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4088\/JCP.11m06837","volume":"72","author":"MH Trivedi","year":"2011","unstructured":"Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, et al. Concise health risk tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011;72:757\u201364.","journal-title":"J Clin Psychiatry"},{"key":"180_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1192\/bjp.180.5.461","volume":"180","author":"JC Mundt","year":"2002","unstructured":"Mundt JC, Marks IM, Shear MK, Greist JH. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461\u20134.","journal-title":"Br J Psychiatry"},{"key":"180_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/art.10993","volume":"49","author":"O Sangha","year":"2003","unstructured":"Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49:156\u201363.","journal-title":"Arthritis Rheum"},{"key":"180_CR25","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1017\/S0033291706008257","volume":"36","author":"M Zimmerman","year":"2006","unstructured":"Zimmerman M, Chelminski I. A scale to screen for DSM-IV Axis I disorders in psychiatric out-patients: performance of the Psychiatric Diagnostic Screening Questionnaire. Psychol Med. 2006;36:1601\u201311.","journal-title":"Psychol Med"},{"key":"180_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/archgenpsychiatry.2010.179","volume":"68","author":"RH Perlis","year":"2011","unstructured":"Perlis RH, Uher R, Ostacher M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011;68:351\u201360.","journal-title":"Arch Gen Psychiatry"},{"key":"180_CR27","doi-asserted-by":"crossref","unstructured":"Zimmerman M, Mattia JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry. 2001b;58:787\u201394.","DOI":"10.1001\/archpsyc.58.8.787"},{"key":"180_CR28","doi-asserted-by":"crossref","unstructured":"Zimmerman M, Mattia JI. The psychiatric diagnostic screening questionnaire: development, reliability and validity. Compr Psychiatry. 2001a;42:175\u201389.","DOI":"10.1053\/comp.2001.23126"},{"key":"180_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.4088\/JCP.11m07043","volume":"73","author":"SC Sung","year":"2012","unstructured":"Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, et al. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry. 2012;73:967\u201376.","journal-title":"J Clin Psychiatry"},{"key":"180_CR30","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1017\/S0033291712001742","volume":"43","author":"SC Sung","year":"2013","unstructured":"Sung SC, Wisniewski SR, Balasubramani GK, Zisook S, Kurian B, Warden D, et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol Med. 2013;43:945\u201360.","journal-title":"Psychol Med"},{"key":"180_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jad.2014.11.026","volume":"174","author":"SC Sung","year":"2015","unstructured":"Sung SC, Wisniewski SR, Luther JF, Trivedi MH, Rush AJ. Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. J Affect Disord. 2015;174:157\u201364.","journal-title":"J Affect Disord"},{"key":"180_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1176\/appi.ajp.2015.14020181","volume":"172","author":"BA Arnow","year":"2015","unstructured":"Arnow BA, Blasey C, Williams LM, Palmer DM, Rekshan W, Schatzberg AF, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry. 2015;172:743\u201350.","journal-title":"Am J Psychiatry"},{"key":"180_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2011.04.032","volume":"133","author":"WV Bobo","year":"2011","unstructured":"Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M. et al. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord. 2011;133:467\u201376.","journal-title":"J Affect Disord"},{"key":"180_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.euroneuro.2011.07.010","volume":"22","author":"ES Friedman","year":"2012","unstructured":"Friedman ES, Davis LL, Zisook S, Wisniewski SR, Trivedi MH, Fava M. et al. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol. 2012;22:183\u201399.","journal-title":"Eur Neuropsychopharmacol"},{"key":"180_CR35","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archpsyc.65.8.870","volume":"65","author":"AJ Rush","year":"2008","unstructured":"Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M. et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65:870\u201380.","journal-title":"Arch Gen Psychiatry"},{"key":"180_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.brs.2011.02.003","volume":"5","author":"G Perugi","year":"2012","unstructured":"Perugi G, Medda P, Zanello S, Toni C, Cassano GB. Episode length and mixed features as predictors of ECT nonresponse in patients with medication-resistant major depression. Brain Stimul. 2012;5:18\u201324.","journal-title":"Brain Stimul"},{"key":"180_CR37","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jad.2011.05.005","volume":"136","author":"JK Rybakowski","year":"2012","unstructured":"Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. J Affect Disord. 2012;136:e13\u2013e19.","journal-title":"J Affect Disord"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0180-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0180-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:54Z","timestamp":1684616634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0180-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0180-z","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ms. Malchow and Mr. Grannemann have no potential conflicts of interest. Dr. Jha has received contract research support from Acadia Pharmaceuticals and Janssen. Dr. Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp, Johnson and Johnson (Jannsen), Liva-Nova, Mind Linc., Sunovion, Taj Medical; speaking fees from Liva-Nova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX. (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Trivedi, is or has been an advisor\/consultant and received fee from: Alkermes, AstraZeneca, Cerecor, Eli Lilly & Company, Lundbeck, Naurex, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., and Takeda. In addition, he has received grants\/research support from National Institute of Mental Health and National Institute on Drug Abuse.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}